Bilateral AMD and comorbidities can negatively affect injection adherence, while clinician consistency and caregiver education can encourage it.

MCO-010, an optogenetic therapy, demonstrated long-term safety and improved quality of life in patients with retinitis ...

An expert outlines vision-preserving strategies for monocular high-risk GA, emphasizing early intervention and tailored ...

4D Molecular Therapeutics (4DMT) released positive interim 1.5- to 3.5-year data from the phase 1/2 PRISM clinical trial ...

Eyepoint Pharma ( ($EYPT) ) has released its Q3 earnings. Here is a breakdown of the information Eyepoint Pharma presented to its investors.

Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.

Jay will begin with a review of recent corporate updates and discuss our clinical programs for DuraVu in wet AMD and DME.

Bispecific antibody treatments remain a promising treatment for diabetic macular edema (DME), as a new study shows that faricimab was effective and had durable results after a year of real-world ...

A 70-year-old man presented to Tufts emergency department with a 2-day history of left eye redness and periorbital swelling ...

Ocular Therapeutix Inc (OCUL) showcases robust trial progress and financial positioning, while navigating regulatory and ...

“In people who have diabetes, when they’re on GLP-1s, they experience an early increase in the risk of diabetic retinopathy,” ...

Cash balance of $344.8 million as of September 30, 2025, together with net proceeds of ~$445 million from October 2025 equity offering, with expected runway into 2028 BEDFORD, Mass., Nov. 04, 2025 ...